MCID: MTR003
MIFTS: 50

Mitral Valve Stenosis

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Mitral Valve Stenosis

MalaCards integrated aliases for Mitral Valve Stenosis:

Name: Mitral Valve Stenosis 12 43 15 17 71
Mitral Stenosis 12 29 54 6 15 32
Rheumatic Mitral Stenosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1754
MeSH 43 D008946
NCIt 49 C50654
SNOMED-CT 67 79619009
ICD10 32 I05.0 I05.2
UMLS 71 C0026269 C0264766

Summaries for Mitral Valve Stenosis

Disease Ontology : 12 A mitral valve disease that is characterized by the narrowing of the orifice of the mitral valve of the heart.

MalaCards based summary : Mitral Valve Stenosis, also known as mitral stenosis, is related to cardiogenic shock and atrial standstill 1. An important gene associated with Mitral Valve Stenosis is NPPA (Natriuretic Peptide A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Angiotensin II and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and testes.

Wikipedia : 74 Mitral stenosis is a valvular heart disease characterized by the narrowing of the orifice of the mitral... more...

Related Diseases for Mitral Valve Stenosis

Diseases in the Mitral Valve Stenosis family:

Congenital Mitral Valve Insufficiency and/or Stenosis

Diseases related to Mitral Valve Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 579)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 31.1 NPPB CRP
2 atrial standstill 1 31.0 NPPB NPPA ACE
3 infective endocarditis 30.8 PPBP PF4 F2 CRP
4 hypoplastic left heart syndrome 30.8 NPPB NPPA ACE
5 endocarditis 30.7 SERPINC1 PPBP PF4 F2 CRP
6 congestive heart failure 30.6 REN NPPB NPPA CRP ACE
7 patent ductus arteriosus 1 30.6 REN PDZK1IP1 NPPB CRP ACE
8 orthostatic intolerance 30.6 REN PPBP ACE
9 heparin-induced thrombocytopenia 30.5 SERPINC1 PF4 F3
10 pericarditis 30.5 NPPB CRP ACE
11 hemopericardium 30.5 F3 F2
12 acute kidney failure 30.4 REN NPPA F2
13 pulmonary disease, chronic obstructive 30.3 SERPINA3 NPPB CRP ACE
14 coronary heart disease 1 30.3 SELP NPPB CRP ACE
15 constrictive pericarditis 30.3 WBP2NL NPPB CRP ARSL ACE
16 hypertrophic cardiomyopathy 30.3 REN NPPB NPPA ATP2A2 ACE
17 aortic valve insufficiency 30.2 REN PDZK1IP1 NPPB CRP ARSL ACE
18 cardiac arrest 30.2 SELP REN NPPB ACE
19 deficiency anemia 30.2 SERPINC1 SELP NPPA CRP ACE
20 sarcoidosis 1 30.2 SERPINA3 SELP CRP ACE
21 pulmonary venoocclusive disease 30.1 WBP2NL PDZK1IP1 NPPB
22 coronary stenosis 30.1 NPPB CRP ACE
23 branch retinal artery occlusion 30.1 SERPINC1 F2 CRP
24 mediastinitis 30.1 F3 F2 CRP
25 central retinal artery occlusion 30.1 SERPINC1 F2 CRP
26 systolic heart failure 30.0 NPPB NPPA CRP ACE
27 hypertensive heart disease 30.0 REN NPPB NPPA ACE
28 hemoglobin e disease 30.0 SERPINA3 F2
29 aortic disease 30.0 SERPINA3 REN CRP ACE
30 atherosclerosis susceptibility 30.0 SELP F3 CRP ACE
31 angina pectoris 30.0 NPPB F3 CRP ACE
32 mitral valve insufficiency 30.0 REN PDZK1IP1 NPPB NPPA F2 CRP
33 cardiac tamponade 29.9 REN NPPB F3 F2 CRP ACE
34 sleep disorder 29.9 REN CRP ACE
35 syphilis 29.9 SERPINA3 F2 CRP ACE
36 pulmonary edema 29.9 SERPINC1 REN NPPB NPPA F2 CRP
37 tetralogy of fallot 29.9 REN NPPB NPPA CRP ACE
38 retinal artery occlusion 29.8 SERPINC1 F2 CRP ACE
39 toxic shock syndrome 29.8 SERPINC1 F3 CRP
40 eclampsia 29.8 SERPINC1 REN F2 ACE
41 takayasu arteritis 29.8 SERPINC1 F3 F2 CRP
42 carotid stenosis 29.8 SELP REN CRP ACE
43 thrombophilia due to activated protein c resistance 29.8 SERPINC1 PF4 F3 F2
44 arteriosclerosis 29.7 SERPINC1 SELP F3 CRP ACE
45 lung disease 29.7 SERPINA3 NPPB F3 CRP ACE
46 sleep apnea 29.7 SELP REN NPPB CRP ACE
47 pneumonia 29.6 F3 F2 CRP ACE
48 chronic kidney disease 29.6 SERPINA3 REN NPPB NPPA CRP ACE
49 exanthem 29.6 F3 F2 CRP ACE
50 thrombosis 29.6 SERPINC1 SERPINA3 SELP PPBP PF4 F3

Comorbidity relations with Mitral Valve Stenosis via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Aortic Valve Disease 1
Bronchitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Mitral Valve Disease
Pulmonary Hypertension, Primary, 1 Respiratory Failure
Rheumatic Heart Disease Rheumatic Myocarditis
Sinoatrial Node Disease Transient Cerebral Ischemia
Tricuspid Valve Disease

Graphical network of the top 20 diseases related to Mitral Valve Stenosis:



Diseases related to Mitral Valve Stenosis

Symptoms & Phenotypes for Mitral Valve Stenosis

Drugs & Therapeutics for Mitral Valve Stenosis

Drugs for Mitral Valve Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Dobutamine Approved Phase 4 34368-04-2 36811
8
Hydralazine Approved Phase 4 86-54-4 3637
9
Simendan Investigational Phase 4 131741-08-7
10
Dabigatran Investigational Phase 4 211914-51-1
11 Angiotensin II Type 1 Receptor Blockers Phase 4
12 Angiotensinogen Phase 4
13 Giapreza Phase 4
14 Neurotransmitter Agents Phase 4
15 Adrenergic Agents Phase 4
16 Calamus Phase 4
17 Adrenergic beta-Agonists Phase 4
18 Cardiotonic Agents Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Adrenergic Agonists Phase 4
22 Sympathomimetics Phase 4
23 Protective Agents Phase 4
24 Antihypertensive Agents Phase 4
25 Angiotensin-Converting Enzyme Inhibitors Phase 4
26 Adrenergic beta-Antagonists Phase 4
27 Vasodilator Agents Phase 4
28 Angiotensin Receptor Antagonists Phase 4
29 Mineralocorticoid Receptor Antagonists Phase 4
30 Mineralocorticoids Phase 4
31 LCZ 696 Phase 4
32
Atenolol Approved Phase 3 29122-68-7 2249
33
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
34
Ramipril Approved Phase 3 87333-19-5 5362129
35
Thrombin Approved, Investigational Phase 3
36
Protein C Approved Phase 3
37 Adrenergic beta-1 Receptor Antagonists Phase 3
38 Sympatholytics Phase 3
39 Adrenergic Antagonists Phase 3
40 Anti-Arrhythmia Agents Phase 3
41 Trace Elements Phase 3
42 Hemostatics Phase 3
43 Nutrients Phase 3
44 Micronutrients Phase 3
45 Coagulants Phase 3
46 Antifibrinolytic Agents Phase 3
47 Antidotes Phase 3
48 protein S Phase 3
49 Vitamin K 1 Phase 3
50 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
2 Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4 antithrombin III
3 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
4 Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement Completed NCT01641614 Phase 4
5 The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery. Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
6 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
7 Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study) Recruiting NCT02426944 Phase 4 NOAC
8 Rationale and Design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial Not yet recruiting NCT04045093 Phase 4 Dabigatran etexilate;Warfarin
9 Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin in Patients With Atrial Fibrillation and Mitral Stenosis Among Pakistani Population Withdrawn NCT03673605 Phase 4 Rivaroxaban 15 mg;Warfarin
10 Effect of Ivabradine vs Atenolol on Heart Rate and Effort Tolerance in Patients With Mild to Moderate Mitral Stenosis and Normal Sinus Rhythm Completed NCT01022463 Phase 3 Ivabradine;Atenolol
11 A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation Completed NCT01729871 Phase 3 rivaroxaban;uninterrupted vitamin K antagonist (VKA)
12 Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis? Completed NCT00121901 Phase 3 glyceryl nitrate
13 The Effect of Ramipril in Suppressing Gene Expression of Fibrosis in Cardiac Mitral Stenosis in Patients With Rheumatic Heart Disease Recruiting NCT03991910 Phase 3 Placebos;Ramipril 5Mg Oral Capsule
14 RIvoraxaban Safety and Efficacy in Patients With Mitral Stenosis Recruiting NCT03926156 Phase 3 Rivaroxaban;Warfarin
15 The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery. Not yet recruiting NCT04408430 Phase 2, Phase 3
16 Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction Not yet recruiting NCT03658031 Phase 3 Dapagliflozin 10mg
17 Pilot Trial of Bosentan for Secondary Pulmonary Hypertension Due to Severe Mitral Valve Dysfunction Unknown status NCT01270750 Phase 1, Phase 2 BOSENTAN
18 Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery Completed NCT00903370 Phase 2
19 Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study Recruiting NCT02830204 Phase 2
20 A Novel Adjustable Neochordae Technique in Mitral Valve Repair Not yet recruiting NCT04299334 Phase 1
21 Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I Terminated NCT00265005 Phase 1 alteplase
22 Quantification of Rheumatic Mitral Stenosis With Cardiac Magnetic Resonance Imaging and Comparison With Transthoracic Echocardiography Unknown status NCT00654472
23 P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy Unknown status NCT01906827
24 PERSONALIZE-AF: Non-invasive Characterization of the Mechanisms of Atrial Fibrillation Unknown status NCT02497248
25 A Study to Assess the Effects of Two Commonly Used Mitral Valve Annuloplasty Rings in Mitral Valve Repair on Short-term Outcomes. Unknown status NCT03290872
26 Multicenter Registry Study of Surgery and Transcatheter Intervention for Structural Heart Diseases Unknown status NCT02917980
27 Studies on Assessment of Left Atrial Distensibility to Predict Late Prognosis in Consecutive Patients Received Echocardiographic Examination Unknown status NCT01171040
28 Right Ventricular Function After Mitral Valve Replacement in Rheumatic Heart Disease Patients With Pulmonary Hypertension: Short Term Follow up Unknown status NCT03549052
29 Subclinical Postoperative Atrial Fibrillation Unknown status NCT02522364
30 Late (up to 12 Years) Clinical and Echocardiographic Outcomes of Percutaneous Transvenous Mitral Commissurotomy in Patients With Rheumatic Mitral Stenosis: Continuing Secondary Antibiotic Prophylaxis Does Not Protect Against Late Events Completed NCT04112108
31 ReAl-life Multicentre Survey Evaluating the Status of Stroke Prevention Strategies in Patients With Non-Valvular Atrial Fibrillation in TurKey (RAMSES) Completed NCT02344901
32 Early Percutaneous Mitral Intervention Versus Conventional Management in Asymptomatic Moderate Mitral Stenosis Completed NCT01406353
33 Balloon Valvuloplasty Registry Completed NCT00005199
34 Post-Approval Study Protocol of the St. Jude Medical Biocor and Biocor Supra Valves Completed NCT00636987
35 Prospective Cohort Study Compares Effect of Corrected and Uncorrected Rheumatic Heart Valve of Pregnant Women on Maternal and Fetal Outcomes Completed NCT03029117
36 Does Acute Normovolemic Hemodilution Affect Intraoperative Value of Serum-creatinine Concentration in Patients Undergoing Cardiac Surgery? Completed NCT02831270 hydroxyethyl starch (HES 130/0.6)
37 Impact of Acute Normovolemic Hemodilution on Whole Blood Coagulation Profile During Post-cardiopulmonary Bypass in Cardiac Surgery: Rotational Thromboelastometry Study Completed NCT02502448 hydroxyethyl starch (HES 130/0.6)
38 Tele-rehabilitation of Heart Patients Completed NCT01752192
39 Post-Approval Study for the MOSAIC® Bioprostheses: A Long Term Follow Up Study. Completed NCT01574625
40 Genome-wide Association Study of Susceptibility to Rheumatic Heart Disease in Fiji and New Caledonia Completed NCT02188862
41 Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study Completed NCT02375282
42 Logical Analysis of Data and Cardiac Surgery Risk Completed NCT00081666
43 Impact of Restrictive Fluid Therapy on Renal Function in Severe Preeclamptic Women Submitted to Cesarean Section Under Spinal Anesthesia Completed NCT02214186
44 Impact of Prosthesis-Patient Mismatch on Clinical Outcomes After Mitral Valve Replacement Completed NCT00629902
45 Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren Completed NCT02353663
46 Determination of Mitral Valve Area After Mitral Valve Repair Surgery for Mitral Stenosis Using 3-dimensional Transesophageal Echocardiography Completed NCT01694251
47 EVALUATION OF TWO SECONDARY CARE STRATEGIES AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA): ACHEIVED TARGET LDL-C TO 100 mg/dL (+/- 10,mg/dL) OR LESS THAN 70 mg/dL. Completed NCT01252875
48 Individualised Follow-up After Valve Surgery Completed NCT03053778
49 Self-Directed Study Using MP3 Players Versus Multimedia Lecture to Improve Auscultation Proficiency of Physicians: A Randomized, Controlled Trial. Completed NCT01596465
50 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation Completed NCT01172184

Search NIH Clinical Center for Mitral Valve Stenosis

Cochrane evidence based reviews: mitral valve stenosis

Genetic Tests for Mitral Valve Stenosis

Genetic tests related to Mitral Valve Stenosis:

# Genetic test Affiliating Genes
1 Mitral Stenosis 29

Anatomical Context for Mitral Valve Stenosis

MalaCards organs/tissues related to Mitral Valve Stenosis:

40
Heart, Lung, Testes, Brain, Kidney, Liver, Skeletal Muscle

Publications for Mitral Valve Stenosis

Articles related to Mitral Valve Stenosis:

(show top 50) (show all 9620)
# Title Authors PMID Year
1
The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis. 54 61
17186137 2007
2
Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty. 61 54
17131174 2007
3
Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. 54 61
17044373 2006
4
Effects of percutaneous balloon mitral valvuloplasty on plasma B-type natriuretic peptide in rheumatic mitral stenosis with and without atrial fibrillation. 54 61
16116870 2005
5
Left atrial diameter is a simple indicator of a deficiency in atrial natriuretic peptide secretion in patients with mitral stenosis: efficacy of postoperative supplementation with synthetic human alpha-atrial natriuretic peptide. 61 54
15550792 2004
6
Increased plasma levels of soluble P-selectin in rheumatic mitral stenosis. 54 61
15249442 2004
7
Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. 61 54
14973795 2004
8
An abnormal systemic and regional hypercoagulable state in patients with mitral stenosis. 61 54
15061299 2004
9
Left atrial platelet activity with rheumatic mitral stenosis: correlation study of severity and platelet P-selectin expression by flow cytometry. 54 61
14605032 2003
10
Hypercoagulability existing in the local left atrium of patient with mitral stenosis. 61 54
12935411 2003
11
Neurohormones in mitral stenosis before and after percutaneous balloon mitral valvotomy. 61 54
12000158 2002
12
Low dose synthetic human atrial natriuretic peptide infusion in a patient with mitral stenosis and severe pulmonary hypertension. 54 61
10553928 1999
13
[Detection of CD62P (GMP-140) on peripheral blood platelet membrane in various heart diseases]. 61 54
7540229 1995
14
Coagulation activity is increased in the left atrium of patients with mitral stenosis. 54 61
7646626 1995
15
Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. 54 61
7817907 1995
16
Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. 61 54
7874858 1994
17
[The acute and 24-hour modifications to the atrial natriuretic factor in patients who have undergone mitral valvuloplasty. The hemodynamic and echocardiographic correlations]. 61 54
8163101 1993
18
Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. 54 61
8425293 1993
19
Atrial natriuretic peptide and bronchial hyperresponsiveness in patients with mitral stenosis. 54 61
8341858 1993
20
Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. 54 61
1442497 1992
21
Direct secretion from left atrium and pulmonary extraction of human atrial natriuretic peptide. 61 54
1532284 1992
22
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients. 61 54
1829375 1991
23
Effects of percutaneous transvenous mitral commissurotomy on levels of plasma atrial natriuretic peptide during exercise. 61 54
1824734 1991
24
Atrial natriuretic peptide response to postural changes in patients with left atrial hypertension. 61 54
1963407 1990
25
Stimulation of atrial natriuretic peptide and vasopressin during retrograde mitral valvuloplasty. 54 61
2147351 1990
26
Atrial natriuretic peptide and vasopressin during percutaneous transvenous mitral valvuloplasty and relation to renin-angiotensin-aldosterone system and renal function. 61 54
2138848 1990
27
Baseline and post-atrial pacing release of atrial natriuretic factor in mitral stenosis. 54 61
2136967 1990
28
[Atrial natriuretic factor. Role in the physiopathology of cardiac and renal diseases]. 54 61
2137235 1990
29
Mitral regurgitation and dyspnoea: the expanding role of mitral effective regurgitant orifice among un-selected patients. 61
32443135 2020
30
Entire mitral reconstruction with porcine extracellular matrix in an acute porcine model. 61
31548077 2020
31
Cardiovascular abnormalities in patient with Williams-Beuren syndrome. 61
31860063 2020
32
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. 61
32474206 2020
33
Mitral Stenosis After MitraClip: How to Avoid and How to Treat. 61
32500412 2020
34
Exacerbation of mitral regurgitation after tricuspid valve replacement for isolated tricuspid regurgitation. 61
32506589 2020
35
Fetal aortic valvuloplasty: first report of two cases from Saudi Arabia. 61
32571360 2020
36
Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition. 61
32175673 2020
37
Calcific Mitral Stenosis: Echoes of Aging. 61
32553259 2020
38
Stenotic double-orifice mitral valve after surgical repaired partial atrioventricular septal defect. 61
32535933 2020
39
Assessment of right ventricular dysfunction in patients with mitral stenosis: A speckle tracking study. 61
31794088 2020
40
Novel Prognostic Score for Immediate and Late Success After Percutaneous Mitral Balloon Commissurotomy in Patients With Mitral Stenosis. 61
32269178 2020
41
Left ventricular diastolic function in mitral stenosis. 61
32562447 2020
42
The Natural History of Severe Calcific Mitral Stenosis. 61
32553258 2020
43
Role of 3-dimensional transesophageal echocardiography in guiding transcatheter mitral valve replacement. 61
32453888 2020
44
Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement? 61
31408104 2020
45
Novel Trigone-Based Sizing Method for Mitral Ring Annuloplasty. 61
31586611 2020
46
Cardiac auscultation skills among junior doctors: effects of sound simulation lesson. 61
32434152 2020
47
Degenerative Mitral Stenosis Versus Rheumatic Mitral Stenosis. 61
32241552 2020
48
Ten-year trends in the incidence, treatment and outcomes of patients with mitral stenosis in Korea. 61
32029525 2020
49
Massive hemoptysis in a pregnant woman: the first rare presentation of mitral valve stenosis. 61
32388966 2020
50
Acute fulminant hemolysis after transcatheter mitral valve replacement for mitral annular calcification. 61
32374902 2020

Variations for Mitral Valve Stenosis

ClinVar genetic disease variations for Mitral Valve Stenosis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LSM1 NM_014462.3(LSM1):c.231+4A>CSNV Uncertain significance 623485 rs775468919 8:38027316-38027316 8:38169798-38169798

Expression for Mitral Valve Stenosis

Search GEO for disease gene expression data for Mitral Valve Stenosis.

Pathways for Mitral Valve Stenosis

GO Terms for Mitral Valve Stenosis

Cellular components related to Mitral Valve Stenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 SERPINC1 SERPINA3 REN PPBP PF4 NPPB
2 collagen-containing extracellular matrix GO:0062023 9.63 SERPINC1 SERPINA3 PF4 NPPA F3 F2
3 extracellular space GO:0005615 9.47 SERPINC1 SERPINA3 SELP REN PPBP PF4
4 platelet alpha granule lumen GO:0031093 9.43 SERPINA3 PPBP PF4

Biological processes related to Mitral Valve Stenosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.72 SERPINA3 SELP PPBP PF4 CRP
2 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.54 PPBP PF4 F2
3 amyloid-beta metabolic process GO:0050435 9.52 REN ACE
4 cardiac muscle hypertrophy in response to stress GO:0014898 9.51 NPPA ATP2A2
5 negative regulation of systemic arterial blood pressure GO:0003085 9.49 NPPB NPPA
6 regulation of blood coagulation GO:0030193 9.48 SERPINC1 F2
7 angiotensin maturation GO:0002003 9.46 REN ACE
8 cGMP biosynthetic process GO:0006182 9.43 NPPB NPPA
9 hemostasis GO:0007599 9.43 SERPINC1 F3 F2
10 receptor guanylyl cyclase signaling pathway GO:0007168 9.4 NPPB NPPA
11 acute-phase response GO:0006953 9.33 SERPINA3 F2 CRP
12 platelet degranulation GO:0002576 9.26 SERPINA3 SELP PPBP PF4
13 regulation of blood pressure GO:0008217 8.92 REN NPPB NPPA ACE

Molecular functions related to Mitral Valve Stenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CXCR chemokine receptor binding GO:0045236 9.16 PPBP PF4
2 hormone receptor binding GO:0051427 8.96 NPPB NPPA
3 heparin binding GO:0008201 8.92 SERPINC1 SELP PF4 F2

Sources for Mitral Valve Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....